Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced 2023-08-25 10:06
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2% 2023-03-22 11:15
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital 2022-01-29 11:37
3SBio announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development 2021-08-26 22:09
3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth 2021-03-31 09:11
3SBio Inc. received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212 2020-11-23 21:28
3SBio MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry 2020-09-02 02:15
3SBio Unveils 2019 Annual Results: Revenue Rises by 16.0%, Normalized Net Profit attributable to owners of the parent Jumps by19.4%, R&D Expenses Soar 45.2% 2020-03-31 12:29
3SBio Selects Verseau's PSGL-1-targeted Antibody VTX-0811 as First Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration 2019-11-18 08:30
Submission and acceptance of application for the production of new drug for Yisaipu(R)aqueous injection solution 2019-07-29 21:42
3SBio Unveils 2018 Annual Results: Revenue Soars by 22.7%, Normalized Net Profit Soars by 29.0%, R&D Expenses Jumps Over 40% 2019-03-21 00:14
3SBio and TLC Form Exclusive Partnership to Commercialize Two NanoX(TM) Products in Mainland China 2019-03-04 07:00
3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies 2019-02-11 20:19
3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies 2019-02-11 20:18
3SBio Unveils 2017 Annual Results: Revenue Soars by 33.5% 2018-03-26 22:09
China FDA Approves New Once-Weekly Bydureon(R) to Improve Glycemic Control in Patients with Type-2 Diabetes 2018-01-04 14:46
3SBio Accelerates Expansion of its Global Biologics Platform by Acquiring the Canadian Biomanufacturing Business of Therapure 2017-09-03 21:01
3SBio Inc. Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer 2017-01-09 16:00
3SBio Inc. Selected as a Constituent of the MSCI China Index 2016-05-13 17:00
3SBio's PEG-irinotecan Wins IND Approval From China FDA 2016-03-07 17:24
1 2